Calidi Biotherapeutics, Inc. CLDI
1.13
(0.07)
(5.83%)
as of 25 Sep
- Market cap
- $3.0M
- P/E
- 0.0×
Follow CLDI
| Dec '17 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|
P/E ratio |
— | — | 0.00 | — | — | — |
P/S ratio |
— | — | 0.00 | — | — | — |
P/FCF ratio |
— | — | 0.00 | — | — | — |
P/Operating CF |
— | — | (22.04) | — | — | — |
P/B ratio |
— | — | 0.00 | — | — | — |
Price to Tangible BV |
— | — | 0.00 | — | — | — |
EV/Sales |
— | — | 0.00 | — | — | — |
EV/EBITDA |
— | — | 0.00 | — | — | — |
EV/Operating CF |
— | — | (6.52) | — | — | — |
EV/FCF |
— | — | (6.52) | — | — | — |
Quick Ratio |
— | 2.59 | 0.01 | 0.19 | 1.01 | 1.42 |
Current Ratio |
— | 3.61 | 0.02 | 0.42 | 1.08 | 1.59 |
Net Debt/EBITDA |
— | 0.60 | (0.03) | (0.01) | 0.44 | 0.26 |
Debt/Assets |
0.00% | 0.00% | 43.97% | 22.72% | 5.25% | 8.70% |
Debt/Equity |
— | 0.00 | (0.02) | (0.28) | 0.38 | 0.21 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
— | (0.32) | 0.52 | 0.92 | 0.83 | 0.83 |
Capex/Depreciation |
— | — | (1.14) | (0.35) | (0.01) | (0.07) |
Interest Coverage |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| — | 0.00% | 78.08% | 99.59% | 759.98% | (893.28%) | |
| — | 2.92% | (21.70%) | (463.16%) | (196.80%) | (222.05%) | |
ROIC |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
— | 315.76% | 61.54% | 627.09% | (1,488.38%) | (824.60%) |
Average Days of Receivables |
— | — | 0.00 | — | — | — |
Research and Development Expense of Revenue |
— | — | 16,126.67% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | — | 35,337.78% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | 10,048.89% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
— | — | (0.61) | — | — | — |
Graham Number |
— | — | 38,485.78 | — | — | — |
Earnings Yield |
— | — | (29.58%) | — | — | — |
Free Cash Flow Yield |
— | — | (15.47%) | — | — | — |
Revenue per Share |
— | 0.00 | 10.23 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
— | (360.97) | (3,003.18) | (3,066.25) | (472.28) | (79.19) |
Capex per Share |
— | 0.00 | (97.27) | (66.48) | (0.38) | (0.45) |
Free Cash Flow per Share |
— | (360.97) | (3,100.45) | (3,132.73) | (472.66) | (79.63) |
Cash per Share |
— | 354.23 | 84.55 | 221.48 | 230.00 | 20.83 |
Shareholders Equity per Share |
— | (4,895.60) | (11,463.64) | (935.80) | 47.19 | 13.98 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | (4,895.60) | (11,463.64) | (935.80) | 47.19 | 13.98 |
Free Cash Flow |
— | (1.08) | (13.64) | (27.57) | (19.71) | (21.41) |
Working Capital |
— | 1.07 | (42.20) | (5.93) | 0.73 | 2.32 |
Capital Expenditures |
— | — | (0.43) | (0.58) | (0.02) | (0.12) |
Net Current Asset Value |
— | (244.97) | (52.25) | (13.95) | (1.99) | 1.16 |
EV/EBIT |
— | — | 0.00 | — | — | — |
Capex to Sales |
— | — | 9.51 | 0.00 | 0.00 | 0.00 |
Net Profit Margin |
— | 0.00% | (56,504.44%) | 0.00% | 0.00% | 0.00% |
Price to Operating Income |
— | — | 0.00 | — | — | — |
| Other line items | ||||||
Depreciation/Fixed assets |
— | — | 0.42 | 1.33 | 1.82 | 2.11 |
Cash ROIC |
— | 7.95% | 28.82% | 704.56% | (167.12%) | (217.91%) |
Accounts Receivable Turnover |
— | — | 0.00 | — | — | — |
Accounts Payable Turnover |
— | — | 0.01 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | 0.00 | — | — | — |
Average Days of Payables |
— | 0.00 | 59,208.21 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | 0.00 | — | — | — |
Average Payables |
— | — | 1.17 | 2.57 | 2.48 | 1.34 |
Average Assets |
— | 115.88 | 117.18 | 6.31 | 12.10 | 11.52 |
Average Common Equity |
— | — | (32.56) | (29.34) | (3.13) | 2.86 |
Columns are period end dates